{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:04:40Z","timestamp":1777644280787,"version":"3.51.4"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.16864","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T15:31:52Z","timestamp":1600183912000},"page":"e2016864","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of Cardiac Events Associated With Azithromycin vs Amoxicillin"],"prefix":"10.1001","volume":"3","author":[{"given":"Haridarshan","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes, and Policy, College of Pharmacy, University of Illinois at Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory S.","family":"Calip","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes, and Policy, College of Pharmacy, University of Illinois at Chicago"},{"name":"Flatiron Health, Inc, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"DiDomenico","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes, and Policy, College of Pharmacy, University of Illinois at Chicago"},{"name":"Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen T.","family":"Schumock","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes, and Policy, College of Pharmacy, University of Illinois at Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie J.","family":"Suda","sequence":"additional","affiliation":[{"name":"Center for Health Equity Research and Promotions, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"},{"name":"Department of Medicine, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd A.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes, and Policy, College of Pharmacy, University of Illinois at Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"issue":"2","key":"zoi200618r1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/phar.v40.2","article-title":"Prevalence of cardiac risk factors in patients prescribed azithromycin before and after the 2012 FDA warning on the risk of potentially fatal heart rhythms.","volume":"40","author":"Patel","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"10","key":"zoi200618r2","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1128\/AAC.44.10.2630-2637.2000","article-title":"Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats.","volume":"44","author":"Ohtani","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"zoi200618r3","first-page":"155","article-title":"Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports.","volume":"1","author":"Hancox","year":"2013","journal-title":"Ther Adv Infect Dis"},{"issue":"20","key":"zoi200618r4","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death.","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi200618r6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1370\/afm.1601","article-title":"Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death.","volume":"12","author":"Rao","year":"2014","journal-title":"Ann Fam Med"},{"issue":"4","key":"zoi200618r7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/cid\/ciu914","article-title":"Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and \u00df-lactam\/\u00df-lactamase inhibitors: a Taiwanese nationwide study.","volume":"60","author":"Chou","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"18","key":"zoi200618r8","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1056\/NEJMoa1300799","article-title":"Use of azithromycin and death from cardiovascular causes.","volume":"368","author":"Svanstr\u00f6m","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi200618r9","doi-asserted-by":"publisher","first-page":"E560","DOI":"10.1503\/cmaj.160355","article-title":"Use of azithromycin and risk of ventricular arrhythmia.","volume":"189","author":"Trifir\u00f2","year":"2017","journal-title":"CMAJ"},{"issue":"6","key":"zoi200618r10","first-page":"318","article-title":"Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials.","volume":"7","author":"Almalki","year":"2014","journal-title":"Am Health Drug Benefits"},{"issue":"6","key":"zoi200618r11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00438-18","article-title":"Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides.","volume":"62","author":"Gorelik","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"zoi200618r15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/0895-7061(96)00015-5","article-title":"Hypertension and outcomes research: from clinical trials to clinical epidemiology.","volume":"9","author":"Psaty","year":"1996","journal-title":"Am J Hypertens"},{"issue":"12","key":"zoi200618r16","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.jclinepi.2005.04.009","article-title":"Hospital discharge diagnoses of ventricular arrhythmias and cardiac arrest were useful for epidemiologic research.","volume":"58","author":"De Bruin","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"zoi200618r17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/pds.2340","article-title":"A systematic review of validated methods for identifying ventricular arrhythmias using administrative and claims data.","volume":"21","author":"Tamariz","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"zoi200618r18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/pds.v19:6","article-title":"Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data.","volume":"19","author":"Hennessy","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"zoi200618r19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"issue":"2","key":"zoi200618r21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.v10.2","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"6","key":"zoi200618r22","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research.","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"key":"zoi200618r5","unstructured":"US Food and Drug Administration. FDA drug safety communication: azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. Updated February 14, 2018. Accessed February 21, 2018. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm341822.htm"},{"key":"zoi200618r12","unstructured":"Hansen? L. The Truven Health MarketScan databases for life sciences researchers. March 2018. Accessed March 1, 2018. https:\/\/www.ibm.com\/watson-health\/about\/truven-health-analytics"},{"key":"zoi200618r13","unstructured":"Healthcare Cost and Utilization Project (HCUP). Clinical Classifications Software (CCS) for ICD-9-CM. Agency for Healthcare Research and Quality. Updated March 6, 2017. Accessed March 1, 2018. https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/ccs\/ccs.jsp"},{"key":"zoi200618r14","unstructured":"Woosley? RL, Heise? CW, Gallo? T, Tate? J, Woosley? D, Romero? KA. QTdrugs List. Accessed March 1, 2018. https:\/\/www.crediblemeds.org\/"},{"key":"zoi200618r20","unstructured":"Rassen? JA, Doherty? M, Huang? W, Schneeweiss? S. Pharmacoepidemiology toolbox. Accessed June 1, 2019. https:\/\/www.drugepi.org\/?"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2770643\/patel_2020_oi_200618_1599583418.50497.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T15:32:05Z","timestamp":1600183925000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2770643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.16864","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]}}}